While other validation studies in cancer have found acceptable screening performance of the ESAS-A alone for anxiety when compared against the GAD-7 as a gold standard reference [35], one GAD-7 validation study in cancer using a research interview for GAD as a gold standard reference reported a low sensitivity at the recommended cutoff of >10 (sensitivity 55%), but a more acceptable screening performance at a cutoff of ≥7 (sensitivity of 74% and specificity of 77%) [39]. The gene discussed is GAD1; the disease is Anxiety.